PSE (Pseudoephedrine)

Pseudoephedrine (PSE) is a safe and effective active ingredient found in leading cold, allergy, and sinus medicines to provide congestion relief. While over 18 million American families rely on these medicines every year, PSE can also be used in the illegal manufacture of methamphetamine. As a result, some policymakers and law enforcement officials in a number of states support requiring a doctor’s prescription to obtain PSE-containing medicines, even though the vast majority of these medicines are sold to law-abiding consumers.

Preventing Illegal Meth Production

CHPA takes the diversion of its members' medicines very seriously and remains committed to working with elected officials to ensure states have the necessary tools to combat illegal sales of PSE. Mandating prescription-only sale of these common cold medicines, however, would be ineffective and burden those who depend on these medicines for relief with unnecessary and costly visits to the doctor.

Learn More
Image of pseudoephedrine label
Pseudoephedrine in the States

The bipartisan federal Combat Meth Epidemic Act strikes the proper policy balance between restricting pseudoephedrine access for illicit use without unduly burdening consumers seeking safe, effective cold relief. Therefore, state legislators should refrain from overriding federal guidelines requiring prescriptions for these legitimate over-the-counter medications.

Mississippi Repeals PSE Bill

The new law returns PSE to OTC status allowing consumers to purchase 3.6 grams of PSE per day, up to 7.2 grams per month.

Mar 17, 2021

Browse PSE (Pseudoephedrine) Content

Stylized Graphic of DC government buildings

Articles

Polibrief: Consumer Data Privacy: State Efforts to Preserve Privacy

In recent years, the issue of consumer data privacy has become increasingly important as technology continues to advance, and more personal information is collected and shared online. Despite the growing concerns over data privacy, the federal government has yet to enact comprehensive legislation addressing the issue. This lack of federal action has prompted many states to take matters into their own hands and introduce their own data privacy laws to protect their residents.

Apr 16, 2024

Orange CHPA logo on dark blue background

Press Releases and Statements

Kentucky Expands Access to OTC Cold & Allergy Medications Containing PSE

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following the adoption of Kentucky House Bill 386 into law, legislation that will eliminate the state’s annual purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE), which is currently the most restrictive yearly limit nationwide at 24 grams, or roughly a three-month supply.

Apr 8, 2024

Group of Four Professionals in a Corporate Setting sitting in blue chairs

Research Reports

CHPA Cybersecurity & Data Privacy Regulatory Landscape Scan

The purpose of this cybersecurity and data privacy regulatory scan is to understand the current and forthcoming regulatory landscape related to cybersecurity and consumer data privacy.

Jan 20, 2023

Federal Register Notice graphic image with flag, capitol building, and gavel

Newsletters

Federal Register (FR) Notices, September 10, 2021

Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.

Sep 8, 2021

Image of pseudoephedrine label

Press Releases and Statements

Oregon Repeal of Unnecessary OTC Restrictions is a Dose of Good Policy for Consumers and Healthcare

Oregon has repealed a 15-year-old law that banned OTC sales of certain medicines for colds and allergies containing PSE.

Jun 17, 2021

Video

States Reject Prescription Policies for PSE

Jun 17, 2021

Video

CHPA Monthly Recap March 2021

Apr 7, 2021

patient at pharmacy counter

Press Releases and Statements

Major Victory for Consumer Access to OTC Medicine in Mississippi

In a major victory for consumer health, today Mississippi has repealed an 11-year-old law that banned over-the-counter (OTC) sales of certain medicines for colds and allergies containing the decongestant pseudoephedrine (PSE).

Mar 17, 2021

Video

Mississippi Repeals PSE Bill

The new law returns PSE to OTC status allowing consumers to purchase 3.6 grams of PSE per day, up to 7.2 grams per month.

Mar 17, 2021

two flasks and a beaker on a table in a lab

Submission

Comments to DEA: Quotas for Controlled Substances and List I Chemicals

The DEA invited comments on the proposed rule to revise existing regulations that manage quotas for controlled substances and List I chemicals held by DEA-registered manufacturers. We have comments on three areas within the proposed rule.

Dec 23, 2019

Filter Results